OMNICELL, INC. — Director's Dealing 2020

Feb 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OMNICELL, Inc (OMCL)
CIK: 0000926326
Period of Report: 2020-02-13

Reporting Person: Ngo Nhat H (EVP, Marketing, S & B D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-13	Common Stock	A	2218	—	Acquired	29055	Direct
2020-02-13	Common Stock	A	1996	—	Acquired	31051	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-13	Stock Options NQ (Right to Buy)	$90.19	A	8537	Acquired	2030-02-12	Common Stock (8537)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	26837	Direct

Footnotes

F1: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2021 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2021 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance.

F2: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years.

F3: NQ: Shares shall vest ratably over 48 month period, with a year cliff.